Growth hormone treatment of obese women for 5 wk: effect on body composition and adipose tissue LPL activity.

Richelsen B, Pedersen SB, Børglum JD, Møller-Pedersen T, Jørgensen J, Jørgensen JO

The American journal of physiology1 Feb 1994Cited by 75 (Europe PMC)

PMID8141279DOI10.1152/ajpendo.1994.266.2.e211PepBankPUB-08141279

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanNon-randomized trialEfficacy outcome
In obese women, GH reduced total fat mass from 40.5 to 38.4 kg, a 5% reduction (P < 0.01).
In plain wordsIn obese women, total fat mass decreased by 5% during GH treatment.
Peptide
HGH (somatotropin)
Outcome
DecreaseTotal fat mass
Study
n = 9
Outcome group
Body composition · Metabolic and weight
Studied dose
0.03 mg.kg ideal body wt-1.day-1 · 5 wkAs given in this study (human).
Measurements
Fat mass
40.5 kg
baseline
Fat mass
38.4 kg
after GH
Fat mass reduction
5%
GH
Source sentences
Summary
GH treatment significantly reduced the total fat mass from 40.5 to 38.4 kg (i.e., 5% reduction of the total fat mass; P < 0.01), whereas the fat-free mass increased from 50.5 to 53.5 kg (P < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
The investigation was a double-blind placebo-controlled crossover study in which nine obese females were treated with GH (0.03 mg.kg ideal body wt-1.day-1) and placebo for 5 wk.
Report a problemFND-0814127901
02HumanNon-randomized trialEfficacy outcome
In obese women, GH increased fat-free mass from 50.5 to 53.5 kg (P < 0.01).
In plain wordsIn obese women, fat-free mass increased during GH treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseFat-free mass
Study
n = 9
Outcome group
Body composition · Metabolic and weight
Studied dose
0.03 mg.kg ideal body wt-1.day-1 · 5 wkAs given in this study (human).
Measurements
Fat-free mass
50.5 kg
baseline
Fat-free mass
53.5 kg
after GH
Source sentences
Summary
GH treatment significantly reduced the total fat mass from 40.5 to 38.4 kg (i.e., 5% reduction of the total fat mass; P < 0.01), whereas the fat-free mass increased from 50.5 to 53.5 kg (P < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
The investigation was a double-blind placebo-controlled crossover study in which nine obese females were treated with GH (0.03 mg.kg ideal body wt-1.day-1) and placebo for 5 wk.
Report a problemFND-0814127902
03HumanNon-randomized trialEfficacy outcome
In obese women, GH reduced intra-abdominal adipose tissue by 7 +/- 0.3% (P < 0.02).
In plain wordsIn obese women, abdominal fat decreased during GH treatment.
Peptide
HGH (somatotropin)
Outcome
DecreaseIntra-abdominal adipose tissue
Study
n = 9
Outcome group
Body composition · Metabolic and weight
Studied dose
0.03 mg.kg ideal body wt-1.day-1 · 5 wkAs given in this study (human).
Measurements
Adipose tissue reduction
7%
intra-abdominal
Reported uncertainty
0.3%
intra-abdominal reduction
Source sentences
Summary
In addition, GH treatment significantly reduced the intra-abdominal adipose tissue determined by CT scan (reduction by 7 +/- 0.3%; P < 0.02).
1 context sentence(design, population, supporting numbers)
Summary · context
The investigation was a double-blind placebo-controlled crossover study in which nine obese females were treated with GH (0.03 mg.kg ideal body wt-1.day-1) and placebo for 5 wk.
Report a problemFND-0814127903
04HumanNon-randomized trialEfficacy outcome
In obese women, GH reduced adipose tissue at the femur by 7% (P < 0.05).
In plain wordsIn obese women, fat around the thigh decreased during GH treatment.
Peptide
HGH (somatotropin)
Outcome
DecreaseFemoral adipose tissue
Study
n = 9
Outcome group
Body composition · Metabolic and weight
Studied dose
0.03 mg.kg ideal body wt-1.day-1 · 5 wkAs given in this study (human).
Measurements
Adipose tissue reduction
7%
femur level
Source sentences
Summary
CT scan performed at the level of the femur showed a 7% reduction in adipose tissue and a 5% increase in muscle volume in the GH group (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
The investigation was a double-blind placebo-controlled crossover study in which nine obese females were treated with GH (0.03 mg.kg ideal body wt-1.day-1) and placebo for 5 wk.
Report a problemFND-0814127904
05HumanNon-randomized trialEfficacy outcome
In obese women, GH increased muscle volume at the femur by 5% (P < 0.05).
In plain wordsIn obese women, thigh muscle volume increased during GH treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseFemoral muscle volume
Study
n = 9
Outcome group
Body composition · Musculoskeletal
Studied dose
0.03 mg.kg ideal body wt-1.day-1 · 5 wkAs given in this study (human).
Measurements
Muscle volume increase
5%
femur level
Source sentences
Summary
CT scan performed at the level of the femur showed a 7% reduction in adipose tissue and a 5% increase in muscle volume in the GH group (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
The investigation was a double-blind placebo-controlled crossover study in which nine obese females were treated with GH (0.03 mg.kg ideal body wt-1.day-1) and placebo for 5 wk.
Report a problemFND-0814127905
06HumanNon-randomized trialEfficacy outcome
In obese women, GH-mediated adipose tissue reductions showed no clear regional differences.
In plain wordsIn obese women, fat reductions during GH treatment showed no clear differences between body regions.
Peptide
HGH (somatotropin)
Outcome
Direction not reportedRegional adipose tissue reduction
Study
n = 9
Comparator
Other measured regions
Outcome group
Body composition · Metabolic and weight
Studied dose
0.03 mg.kg ideal body wt-1.day-1 · 5 wkAs given in this study (human).
Source sentences
Summary
Thus no clear regional differences in the GH-mediated reduction of the adipose tissue mass were observed.
1 context sentence(design, population, supporting numbers)
Summary · context
The investigation was a double-blind placebo-controlled crossover study in which nine obese females were treated with GH (0.03 mg.kg ideal body wt-1.day-1) and placebo for 5 wk.
Report a problemFND-0814127906
07HumanNon-randomized trialMechanism
In obese women, GH reduced adipose tissue lipoprotein lipase activity by approximately 50% (P < 0.01).
In plain wordsIn obese women, a fat-processing enzyme became less active during GH treatment.
Peptide
HGH (somatotropin)
Outcome
DecreaseAdipose tissue lipoprotein lipase activity
Study
n = 9
Outcome group
Lipids · Metabolic and weight
Studied dose
0.03 mg.kg ideal body wt-1.day-1 · 5 wkAs given in this study (human).
Measurements
LPL activity reduction
≈ 50%
adipose tissue
Source sentences
Summary
GH reduced the LPL activity by approximately 50% (P < 0.01) in the adipose tissue.
1 context sentence(design, population, supporting numbers)
Summary · context
The investigation was a double-blind placebo-controlled crossover study in which nine obese females were treated with GH (0.03 mg.kg ideal body wt-1.day-1) and placebo for 5 wk.
Report a problemFND-0814127907
08HumanNon-randomized trialEfficacy outcome
In obese women, GH significantly increased plasma free fatty acids (P < 0.01).
In plain wordsIn obese women, blood free fatty acids increased during GH treatment.
Peptide
HGH (somatotropin)
Outcome
IncreasePlasma free fatty acids
Study
n = 9
Outcome group
Lipids · Metabolic and weight
Studied dose
0.03 mg.kg ideal body wt-1.day-1 · 5 wkAs given in this study (human).
Source sentences
Summary
Finally, GH treatment significantly increased the level of plasma free fatty acids (P < 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)
1 context sentence(design, population, supporting numbers)
Summary · context
The investigation was a double-blind placebo-controlled crossover study in which nine obese females were treated with GH (0.03 mg.kg ideal body wt-1.day-1) and placebo for 5 wk.
Report a problemFND-0814127908

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.